Sign in or create an account to add this stock to your watchlist.
About Diplomat Pharmacy (NYSE:DPLO)
Diplomat Pharmacy, Inc. operates as an independent specialty pharmacy in the United States. The company stocks, dispenses, and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. It also provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training/consulting, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems. The company's primary focus is on medication management programs for individuals with complex chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialized infusion therapy, and various other serious or long-term conditions. The company was founded in 1975 and is headquartered in Flint, Michigan.
Industry, Sector and Symbol
Industry Drug stores & proprietary stores
Sub-IndustryN/A
SectorRetail/Wholesale
SymbolNYSE:DPLO
CUSIPN/A
Phone888-720-4450
Debt
Debt-to-Equity Ratio0.59
Current Ratio0.88
Quick Ratio0.57
Price-To-Earnings
Trailing P/E Ratio29.24
Forward P/E Ratio26.70
P/E GrowthN/A
Sales & Book Value
Annual Sales$4.49 billion
Price / Sales0.41
Cash Flow$1.8397 per share
Price / Cash13.35
Book Value$10.17 per share
Price / Book2.41
Profitability
EPS (Most Recent Fiscal Year)$0.84
Net Income$15.51 million
Net Margins0.23%
Return on Equity8.80%
Return on Assets4.07%
Miscellaneous
Employees2,419
Outstanding Shares74,130,000
Diplomat Pharmacy (NYSE:DPLO) Frequently Asked Questions
What is Diplomat Pharmacy's stock symbol?
Diplomat Pharmacy trades on the New York Stock Exchange (NYSE) under the ticker symbol "DPLO."
How were Diplomat Pharmacy's earnings last quarter?
Diplomat Pharmacy (NYSE:DPLO) announced its quarterly earnings data on Monday, May, 7th. The company reported $0.20 earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of $0.21 by $0.01. The firm had revenue of $1.34 billion for the quarter, compared to analyst estimates of $1.28 billion. Diplomat Pharmacy had a return on equity of 8.80% and a net margin of 0.23%. Diplomat Pharmacy's revenue for the quarter was up 24.4% compared to the same quarter last year. During the same period in the previous year, the business posted $0.19 EPS. View Diplomat Pharmacy's Earnings History.
When is Diplomat Pharmacy's next earnings date?
What guidance has Diplomat Pharmacy issued on next quarter's earnings?
Diplomat Pharmacy updated its FY18 earnings guidance on Monday, May, 7th. The company provided earnings per share guidance of $0.87-$0.97 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.92. The company issued revenue guidance of $5.5-$5.9 billion, compared to the consensus revenue estimate of $5.44 billion.
What price target have analysts set for DPLO?
11 brokerages have issued 12 month price objectives for Diplomat Pharmacy's stock. Their predictions range from $18.00 to $35.00. On average, they anticipate Diplomat Pharmacy's stock price to reach $26.35 in the next twelve months. View Analyst Ratings for Diplomat Pharmacy.
Who are some of Diplomat Pharmacy's key competitors?
Who are Diplomat Pharmacy's key executives?
Diplomat Pharmacy's management team includes the folowing people:
- Mr. Philip R. Hagerman, Co-Founder & Chairman Emeritus (Age 66)
- Mr. Gary Rice M.B.A., M.S., R.Ph., RPh, MS, MBA, CSP, Exec. VP of Operations (Age 60)
- Mr. Jeffrey G. Park, Interim CEO & Director (Age 46)
- Mr. Joel Saban, Pres (Age 50)
- Mr. Atul Kavthekar, CFO, Treasurer & Principal Accounting Officer
Has Diplomat Pharmacy been receiving favorable news coverage?
News headlines about DPLO stock have trended somewhat positive this week, according to Accern Sentiment. The research firm identifies positive and negative news coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Diplomat Pharmacy earned a daily sentiment score of 0.18 on Accern's scale. They also gave headlines about the company an impact score of 50.21 out of 100, meaning that recent news coverage is somewhat likely to have an impact on the company's share price in the next few days.
Who are Diplomat Pharmacy's major shareholders?
Diplomat Pharmacy's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (8.79%), Frontier Capital Management Co. LLC (5.29%), Dimensional Fund Advisors LP (1.75%), Northern Trust Corp (1.66%), GW&K Investment Management LLC (1.38%) and Cambridge Investment Research Advisors Inc. (1.36%). Company insiders that own Diplomat Pharmacy stock include Atheer A Kaddis, Atul Kavthekar, Jeffrey G Park, Joel Saban and Philip R Hagerman. View Institutional Ownership Trends for Diplomat Pharmacy.
Which institutional investors are selling Diplomat Pharmacy stock?
DPLO stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Cortina Asset Management LLC, BlackRock Inc., Cambridge Investment Research Advisors Inc., JPMorgan Chase & Co., Citigroup Inc., Broadview Advisors LLC and Granite Investment Partners LLC. View Insider Buying and Selling for Diplomat Pharmacy.
Which institutional investors are buying Diplomat Pharmacy stock?
DPLO stock was acquired by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Matarin Capital Management LLC, Hood River Capital Management LLC, Palisade Capital Management LLC NJ, Mackay Shields LLC, Frontier Capital Management Co. LLC, State of Wisconsin Investment Board and Iguana Healthcare Management LLC. Company insiders that have bought Diplomat Pharmacy stock in the last two years include Atul Kavthekar, Jeffrey G Park and Joel Saban. View Insider Buying and Selling for Diplomat Pharmacy.
How do I buy shares of Diplomat Pharmacy?
Shares of DPLO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Diplomat Pharmacy's stock price today?
One share of DPLO stock can currently be purchased for approximately $24.56.
How big of a company is Diplomat Pharmacy?
Diplomat Pharmacy has a market capitalization of $1.82 billion and generates $4.49 billion in revenue each year. The company earns $15.51 million in net income (profit) each year or $0.84 on an earnings per share basis. Diplomat Pharmacy employs 2,419 workers across the globe.
How can I contact Diplomat Pharmacy?
Diplomat Pharmacy's mailing address is 4100 S. SAGINAW ST., FLINT MI, 48507. The company can be reached via phone at 888-720-4450 or via email at [email protected]
MarketBeat Community Rating for Diplomat Pharmacy (DPLO)
MarketBeat's community ratings are surveys of what our community members think about Diplomat Pharmacy and other stocks. Vote "Outperform" if you believe DPLO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DPLO will underperform the S&P 500 over the long term. You may vote once every thirty days.
Diplomat Pharmacy (NYSE:DPLO) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
11 Wall Street analysts have issued ratings and price targets for Diplomat Pharmacy in the last 12 months. Their average twelve-month price target is $26.35, suggesting that the stock has a possible upside of 7.29%. The high price target for DPLO is $35.00 and the low price target for DPLO is $18.00. There are currently 5 hold ratings and 6 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Hold | Hold | Hold |
| Consensus Rating Score: | 2.55 | 2.45 | 2.40 | 2.13 |
| Ratings Breakdown: | 0 Sell Rating(s)
5 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
6 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
6 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
5 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $26.35 | $25.50 | $23.95 | $18.8125 |
| Price Target Upside: | 7.29% upside | 21.26% upside | 0.38% upside | 1.35% downside |
Diplomat Pharmacy (NYSE:DPLO) Consensus Price Target History
Diplomat Pharmacy (NYSE:DPLO) Analyst Ratings History
Show:
(Data available from 5/20/2016 forward)
Diplomat Pharmacy (NYSE:DPLO) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Diplomat Pharmacy (NYSE DPLO) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 30.20%
Institutional Ownership Percentage: 64.28%
Diplomat Pharmacy (NYSE DPLO) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 3/9/2018 | Philip R. Hagerman | Director | Sell | 2,150,000 | $20.65 | $44,397,500.00 | |  |
| 11/20/2017 | Atul Kavthekar | CFO | Buy | 2,000 | $15.00 | $30,000.00 | 2,000 | |
| 11/20/2017 | Jeffrey G Park | Director | Buy | 3,000 | $15.46 | $46,380.00 | 7,640 | |
| 11/20/2017 | Joel Saban | President | Buy | 10,000 | $15.24 | $152,400.00 | 12,000 | |
| 9/15/2016 | Atheer A Kaddis | EVP | Sell | 20,000 | $30.12 | $602,400.00 | 20,000 | |
| 8/1/2016 | Atheer A Kaddis | EVP | Sell | 12,325 | $35.76 | $440,742.00 | 12,325 | |
| 7/1/2016 | Atheer A Kaddis | EVP | Sell | 12,325 | $35.04 | $431,868.00 | 12,325 | |
| 6/1/2016 | Atheer A Kaddis | EVP | Sell | 12,325 | $32.31 | $398,220.75 | 12,325 | |
| 5/2/2016 | Atheer A Kaddis | EVP | Sell | 12,325 | $30.17 | $371,845.25 | 12,325 | |
| 4/15/2016 | Atheer A Kaddis | EVP | Sell | 24,650 | $30.00 | $739,500.00 | 24,650 | |
| 2/12/2016 | Atheer A. Kaddis | EVP | Sell | 12,325 | $30.00 | $369,750.00 | | |
| 12/7/2015 | Philip R Hagerman | CEO | Sell | 2,300,000 | $33.60 | $77,280,000.00 | | |
| 12/1/2015 | Atheer A. Kaddis | SVP | Sell | 12,325 | $34.75 | $428,293.75 | | |
| 12/1/2015 | Gary W. Kadlec | President | Sell | 30,000 | $34.93 | $1,047,900.00 | | |
| 11/3/2015 | Atheer A. Kaddis | SVP | Sell | 24,650 | $30.00 | $739,500.00 | | |
| 11/2/2015 | Gary W. Kadlec | President | Sell | 30,000 | $28.03 | $840,900.00 | | |
| 10/1/2015 | Gary W. Kadlec | President | Sell | 30,000 | $27.66 | $829,800.00 | | |
| 9/8/2015 | Atheer A. Kaddis | SVP | Sell | 12,325 | $37.42 | $461,201.50 | | |
| 9/1/2015 | Gary W. Kadlec | President | Sell | 30,000 | $38.05 | $1,141,500.00 | | |
| 8/26/2015 | Sean Whelan | CFO | Sell | 149,534 | $38.04 | $5,688,273.36 | 142,530 | |
| 3/25/2015 | David C Dreyer | Director | Buy | 1,034 | $29.00 | $29,986.00 | | |
| 3/25/2015 | Jeffrey M Rowe | EVP | Sell | 600,000 | $29.00 | $17,400,000.00 | | |
| 3/25/2015 | Philip R Hagerman | CEO | Sell | 1,801,000 | $29.00 | $52,229,000.00 | | |
| 10/9/2014 | Atheer A Kaddis | SVP | Buy | 4,000 | $13.00 | $52,000.00 | | |
| 10/9/2014 | Jeffrey M Rowe | EVP | Sell | 416,666 | $13.00 | $5,416,658.00 | | |
| 10/9/2014 | Philip R Hagerman | CEO | Sell | 2,916,666 | $13.00 | $37,916,658.00 | | |
| 10/9/2014 | Sean Whelan | CFO | Buy | 2,000 | $13.00 | $26,000.00 | | |
(Data available from 1/1/2013 forward)
Diplomat Pharmacy (NYSE DPLO) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Rite Aid (RAD) versus Diplomat Pharmacy (DPLO) Financial Analysis
www.americanbankingnews.com - May 20 at 7:22 PM |
| $1.42 Billion in Sales Expected for Diplomat Pharmacy (DPLO) This Quarter
www.americanbankingnews.com - May 17 at 3:48 AM |
 | Diplomat Pharmacy Integrates With New Leadership
finance.yahoo.com - May 15 at 5:20 PM |
| Head to Head Contrast: Diplomat Pharmacy (DPLO) & CVS Health (CVS)
www.americanbankingnews.com - May 15 at 1:43 PM |
| Zacks: Brokerages Anticipate Diplomat Pharmacy (DPLO) to Post $0.23 EPS
www.americanbankingnews.com - May 15 at 11:34 AM |
 | Your guide to the Trump drug price plan: who it affects and how
www.marketwatch.com - May 15 at 9:16 AM |
| Contrasting Diplomat Pharmacy (DPLO) and CVS Health (CVS)
www.americanbankingnews.com - May 14 at 11:16 PM |
| Reviewing Diplomat Pharmacy (DPLO) & CVS Health (CVS)
www.americanbankingnews.com - May 14 at 3:23 PM |
| FY2018 EPS Estimates for Diplomat Pharmacy (DPLO) Reduced by Analyst
www.americanbankingnews.com - May 11 at 10:52 AM |
 | ARMO Snapped Up, DEPO Soars On Upbeat Forecast, DPLO Gets A New Boss
www.nasdaq.com - May 11 at 9:28 AM |
 | Diplomat Pharmacy (DPLO) New CEO Removes an Overhang - Cowen
www.streetinsider.com - May 11 at 9:28 AM |
| Equities Analysts Offer Predictions for Diplomat Pharmacy's Q2 2018 Earnings (DPLO)
www.americanbankingnews.com - May 11 at 9:05 AM |
| Diplomat Pharmacy (DPLO) Lifted to "Overweight" at JPMorgan Chase
www.americanbankingnews.com - May 10 at 7:51 PM |
| Why Diplomat Pharmacy Stock Jumped Today
finance.yahoo.com - May 10 at 5:15 PM |
| Diplomat Pharmacy (DPLO) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - May 10 at 1:11 PM |
| Diplomat Pharmacy Appoints Brian Griffin as Chief Executive Officer and Chairman of the Board
finance.yahoo.com - May 10 at 9:01 AM |
| Edited Transcript of DPLO earnings conference call or presentation 8-May-18 12:00pm GMT
finance.yahoo.com - May 10 at 9:01 AM |
| Q3 2018 Earnings Forecast for Diplomat Pharmacy Issued By William Blair (DPLO)
www.americanbankingnews.com - May 10 at 7:50 AM |
| Diplomat Pharmacy (DPLO) Raised to Hold at Zacks Investment Research
www.americanbankingnews.com - May 9 at 9:42 PM |
 | Diplomat Pharmacy's (DPLO) Interim CEO Jeff Park on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 8 at 5:02 PM |
| Diplomat Pharmacy in Final Stages of CEO Search Process
finance.yahoo.com - May 8 at 8:52 AM |
| Diplomat Pharmacy (DPLO) Issues Quarterly Earnings Results
www.americanbankingnews.com - May 7 at 9:12 PM |
| Diplomat Pharmacy misses by $0.02, beats on revenue
seekingalpha.com - May 7 at 5:13 PM |
| Diplomat Pharmacy (DPLO) Issues FY18 Earnings Guidance
www.americanbankingnews.com - May 7 at 5:12 PM |
| DPLO Crosses Below Key Moving Average Level
www.nasdaq.com - May 7 at 5:08 PM |
| Diplomat Pharmaceuticals: 1Q Earnings Snapshot
finance.yahoo.com - May 7 at 5:08 PM |
| Diplomat Announces Strong 1st Quarter Financial Results
finance.yahoo.com - May 7 at 5:08 PM |
 | Daily Technical Summary Reports on Generic Drugs Stocks -- Adamas Pharma, Catalent, Diplomat Pharmacy, and Ironwood Pharma
www.bizjournals.com - May 7 at 8:49 AM |
| Express Scripts (ESRX) & Diplomat Pharmacy (DPLO) Critical Analysis
www.americanbankingnews.com - May 4 at 3:29 PM |
| Reviewing Express Scripts (ESRX) & Diplomat Pharmacy (DPLO)
www.americanbankingnews.com - May 3 at 9:43 PM |
| Diplomat Pharmacy (DPLO) Cut to "Sell" at Zacks Investment Research
www.americanbankingnews.com - May 2 at 12:36 AM |
| Diplomat to Participate in 43rd Annual Deutsche Bank Health Care Conference
finance.yahoo.com - May 1 at 4:51 PM |
| Diplomat Launches CastiaRx, Industry-Leading Specialty Benefit Manager
finance.yahoo.com - April 30 at 8:59 AM |
| Diplomat Pharmacy (DPLO) to Release Earnings on Monday
www.americanbankingnews.com - April 30 at 6:38 AM |
| Analysts Expect Diplomat Pharmacy (DPLO) Will Announce Quarterly Sales of $1.27 Billion
www.americanbankingnews.com - April 29 at 1:54 AM |
| Diplomat Pharmacy (DPLO) Expected to Announce Earnings of $0.21 Per Share
www.americanbankingnews.com - April 27 at 11:24 PM |
| Critical Contrast: CVS Health (CVS) versus Diplomat Pharmacy (DPLO)
www.americanbankingnews.com - April 27 at 1:30 PM |
| Diplomat to Release Q1 2018 Operating Results, Host Conference Call on May 7
finance.yahoo.com - April 23 at 4:51 PM |
| Detailed Research: Economic Perspectives on Craft Brew Alliance, Herc, Diplomat Pharmacy, Western Gas Partners, LP, Stag Industrial, and Genesee & Wyoming — What Drives Growth in Today's Competitive Landscape
finance.yahoo.com - April 23 at 8:40 AM |
| Analyzing Express Scripts (ESRX) and Diplomat Pharmacy (DPLO)
www.americanbankingnews.com - April 15 at 11:30 PM |
| Diplomat Pharmacy (DPLO) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - April 15 at 8:17 AM |
| Diplomat Pharmacy (DPLO) Downgraded by BidaskClub to "Sell"
www.americanbankingnews.com - April 14 at 11:26 PM |
| Edited Transcript of DPLO presentation 7-Mar-17 9:35pm GMT
finance.yahoo.com - April 12 at 9:34 AM |
| Zacks: Brokerages Expect Diplomat Pharmacy (DPLO) Will Announce Quarterly Sales of $1.27 Billion
www.americanbankingnews.com - April 12 at 1:45 AM |
| Brokerages Anticipate Diplomat Pharmacy (DPLO) Will Post Earnings of $0.22 Per Share
www.americanbankingnews.com - April 10 at 11:16 PM |
| Reviewing Diplomat Pharmacy (DPLO) and Walgreens Boots Alliance (WBA)
www.americanbankingnews.com - April 9 at 7:14 AM |
| BidaskClub Upgrades Diplomat Pharmacy (DPLO) to "Buy"
www.americanbankingnews.com - April 8 at 7:00 PM |
| Diplomat Pharmacy (DPLO) Downgraded to "Buy" at BidaskClub
www.americanbankingnews.com - April 7 at 10:55 AM |
| 1-800-PetMeds (PETS) versus Diplomat Pharmacy (DPLO) Head-To-Head Survey
www.americanbankingnews.com - April 6 at 3:10 AM |
| Head-To-Head Contrast: HealthWarehouse.com (HEWA) and Diplomat Pharmacy (DPLO)
www.americanbankingnews.com - April 5 at 9:30 AM |
Diplomat Pharmacy (NYSE:DPLO) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Diplomat Pharmacy (NYSE:DPLO) Income Statement, Balance Sheet and Cash Flow Statement
Diplomat Pharmacy (NYSE DPLO) Stock Chart for Sunday, May, 20, 2018
Loading chart…
